ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation

Highlights

- ALIX regulates EGFR activity and PD-L1 surface presentation in breast cancer cells
- PD-L1 is packaged into the exosomes of breast cancer cells
- ALIX depletion results in reduced exosomal and increased surface PD-L1 expression
- Increased surface PD-L1 is associated with an enhanced immunosuppressive phenotype

Authors

James Monypenny, Hanna Milewicz, Fabian Flores-Borja, ..., Borivoj Vojnovic, Jeremy G. Carlton, Tony Ng

Correspondence

jeremy.carlton@kcl.ac.uk (J.G.C.), tony.ng@kcl.ac.uk (T.N.)

In Brief

Monypenny et al. show that the ESCRT-related protein ALIX regulates two clinically important proteins in breast cancer; namely, EGFR, a receptor linked to cell survival, and PD-L1, an immune checkpoint protein. ALIX is, therefore, associated with pathways that drive both cell-autonomous and non-cell-autonomous mechanisms of tumor survival.
ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation

James Monypenny,1,17 Hanna Milewicz,1,17 Fabian Flores-Borja,1,2,17 Gregory Weitsman,1,17 Anthony Cheung,1,2 Ruhe Chowdhury,1,13 Thomas Burgoyne,1,15 Appitha Arulappu,1 Katherine Lawler,1,13 Paul R. Barber,1,14 Jose M. Vicencio,14 Melanie Keppeler,1 Waizyu Wulaningsih,6 Sean M. Davidson,5 Franca Fraternali,7 Natalie Woodward,8 Mark Turmaine,9 Cheryl Gillett,1 Dafne Franz,14 Sergio A. Quezada,14 Clare E. Futter,15 Alex Von Kriegsheim,10 Walter Koich,10,11,12 Borivoj Vojnovic,4 Jeremy G. Carlton,13,16,* and Tony Ng1,2,14,18,*

1Richard Dimbleby Department of Cancer Research, Randall Division and Division of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Medical School Campus, London SE1 1UL, UK
2KCL Breast Cancer Now Research Unit, Department of Research Oncology, Guy’s Hospital, King’s College London, London SE1 9RT, UK
3Institute for Mathematical and Molecular Biomedicine, King’s College London, Guy’s Medical School Campus, London SE1 1UL, UK
4Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK
5Hatter Cardiovascular Institute, University College London, 67 Cheries Mews, London WC1E 6HX, UK
6Cancer Epidemiology Group, Division of Cancer Studies, King’s College London, London SE1 9RT, UK
7Bioinformatics and Computational Biology, Randall Division, King’s College London, Guy’s Medical School Campus, London SE1 1UL, UK
8KHP Cancer Biobank, King’s College London, Innovation Hub, Guy’s Cancer Centre, London SE1 9RT, UK
9Division of Biosciences, University College London, Gower Street, London WC1E 6BT, UK
10Systems Biology Ireland, University College Dublin, Belfield, Dublin 4, Ireland
11Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
12School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland
13Division of Cancer and Pharmaceutical Sciences, King’s College London, Guy’s Hospital, Great Maze Pond, London, UK
14UCL Cancer Institute, Paul O’Gorman Building, University College London, London WC1E 6DD, UK
15UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK
16Organelle Dynamics Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
17These authors contributed equally
18Lead Contact
*Correspondence: jeremy.carlton@kcl.ac.uk (J.G.C.), tony.ng@kcl.ac.uk (T.N.)
https://doi.org/10.1016/j.celrep.2018.06.066

SUMMARY

The immunosuppressive transmembrane protein PD-L1 was shown to traffic via the multivesicular body (MVB) and to be released on exosomes. A high-content siRNA screen identified the endosomal sorting complexes required for transport (ESCRT)-associated protein ALIX as a regulator of both EGFR activity and PD-L1 surface presentation in basal-like breast cancer (BLBC) cells. ALIX depletion results in prolonged and enhanced stimulation-induced EGFR activity as well as defective PD-L1 trafficking through the MVB, reduced exosomal secretion, and its redistribution to the cell surface. Increased surface PD-L1 expression confers an EGFR-dependent immunosuppressive phenotype on ALIX-depleted cells. An inverse association between ALIX and PD-L1 expression was observed in human breast cancer tissues, while an immuno-competent mouse model of breast cancer revealed that ALIX-deficient tumors are larger and show an increased immunosuppressive environment. Our data suggest that ALIX modulates immunosuppres-

INTRODUCTION

Epidermal growth factor receptor (EGFR) is either amplified or mutated in a variety of cancers and contributes significantly to tumorigenesis (Chong and Jäne, 2013; Ciardiello and Tortora, 2008). Basal-like breast cancer (BLBC), a subtype of disease with the worst therapeutic outcomes, commonly exhibits elevated EGFR expression (Burness et al., 2010; Irshad et al., 2011). While the subject of intense research, the complexity and plasticity of the tumor EGFR signaling network may underlie the poor response to current EGFR-targeted therapies (Hudis and Gianni, 2011). Thus, there is a need to seek additional molecular targets for improving EGFR targeting in basal-like disease.

Immune checkpoint blockade has introduced exciting possibilities to the field of targeted cancer therapy to inhibit tumor growth, with exploitation of programmed death-ligand 1 (PD-L1) showing great therapeutic promise (Pardoll, 2012). The recent demonstration of a direct association between activating EGFR mutations and increased PD-L1 expression in
non-small-cell lung cancer has shown an interdependence between cancer cell-autonomous (EGFR-dependent cell survival) and non-autonomous (PD-L1-dependent evasion of immune surveillance) mechanisms of tumor survival (Akbay et al., 2013; Murillo et al., 2014). Consequently, tumors harboring activating EGFR mutations benefit from two distinct but linked survival pathways, and targeting of mutant EGFR can impair the immunosuppressive phenotype of these tumors (Chen et al., 2015).

However, targeting of wild-type receptors in human lung cancer cell lines has little effect on PD-L1 expression (Azuma et al., 2014), suggesting that the link between EGFR and PD-L1 expression is dependent on the kinase activity of the receptor (Akbay et al., 2013; Azuma et al., 2014). In BLBC, PD-L1 expression is frequently observed alongside elevated wild-type EGFR expression (Irshad et al., 2011; Nielsen et al., 2004), suggesting that the immunosuppressive characteristics of these tumors may be refractory to the effects of therapies targeting EGFR’s kinase activity. A greater understanding of mechanisms driving EGFR signaling in breast cancer is, therefore, warranted; in particular, how EGFR activity in this disease affects immunosuppressive mechanisms of exosome biogenesis and regulation of EGFR activity. We found that PD-L1 is secreted on exosomes in an ALIX-dependent manner, and impaired exosomal release conferred an enhanced immunosuppressive phenotype on tumor cells that was dependent upon EGFR kinase activity. Our data suggest that downregulation of ALIX provides a mechanism for enhancing both EGFR activity and PD-L1-mediated evasion of anti-tumor immunity in BLBC, driving cell-autonomous and non-cell-autonomous mechanisms of tumor survival.

RESULTS

EGF Activity Monitoring In Situ Using a FRET Biosensor

Fluorescence resonance energy transfer (FRET)-based biosensors enable in situ monitoring of signaling pathway activities in cells (Komatsu et al., 2011). The Picchu-X FRET biosensor (Kur- okawa et al., 2001) is based on the CrkII adaptor protein, a direct target of EGFR phosphorylation (Hashimoto et al., 1998). Here, we use a modified version of Picchu-X that has been optimized for fluorescence lifetime imaging (FLIM) to monitor EGFR activity in HCC1954 BLBC cells.

Background biosensor activity in HCC1954 cells was low, indicating a minimal basal EGFR activity (Figure 1A). We observed a stimulation-dependent and PD168393-sensitive enhancement of Picchu-X phosphorylation (Figure 1A) and FRET/FLIM (Figures 1B and 1C), demonstrating the biosensor’s specificity as a readout of EGFR activity. The relationship between mean donor lifetime and mean fluorescence intensity among untreated and EGF-treated populations was incorporated into the analysis.
account for lifetime variations arising from differences in biosensor expression levels (Figure 1D). The analysis confirmed that the association between EGF treatment and lifetime was unaffected by the level of biosensor expression (Figure 1E). This stringent method of analysis was applied to all lifetime data acquired from the high-content small interfering RNA (siRNA) screen.

Identification of Regulators of EGFR Using a FLIM-Based High-Content Screen

We determined the effects of the targeted knockdown of 533 candidate proteins on EGFR signaling in situ to identify regulators of EGFR among a network of candidate proteins extracted from a bioinformatics-led analysis of protein-interaction databases (Figure S1). Twenty hits were identified that abrogated the biosensor response to ligand (Figure 2A, gray nodes; Figure 2B, cf. difference in the slopes of linear regression lines for EGF versus non-EGF treatment cell populations within the example "non-hit" and "hit" siRNA experimental groups; Table S1). Details of the 20 hits identified in the screen are provided in Table S1, and their known interactions with members of the EGFR subnetwork are illustrated in Figure S1 (pink nodes).

ALIX Is a Negative Regulator of EGFR Activity

Of the 20 proteins identified in our screen, 14 were identified as exosomal cargo proteins (Table S2), suggesting that changes in exosomal sorting can influence EGFR activation. There is
increasing realization that cancer cells can exploit the exosomal pathway as a mechanism for driving tumor survival and dissemination (Bissig and Gruenberg, 2014; Ghossoub et al., 2014). Consequently, we sought to identify proteins providing an interface between oncogenic EGFR and exosomal components in BLBC. The expression of 12 of these 14 exosomal-related proteins has been confirmed in normal and cancerous human breast tissues (Table S3). Of these, the adaptor protein ALIX was selected for further investigation, given its association with the exosomal cargo and intraluminal vesicle (ILV) biogenesis (Table S2).

Using HCC1954 cells stably expressing ALIX short hairpin RNA (shRNA), we confirmed that stimulation-induced EGFR phosphorylation was both enhanced and prolonged in ALIX knockdown (KD) cells, when compared with non-targeting controls (NTCs; Figure 2C). Elevated levels of downstream signaling components (endogenous CrkII phosphorylation) were also observed in these cells following EGF stimulation (Figure 2D). Results were confirmed in SKBR3 breast cancer cells (Figure S2), demonstrating that this phenotype was not unique to HCC1954 cells.

**ALIX Controls Exosomal Cargo Incorporation**

ALIX is implicated in the multivesicular body (MVB) sorting pathway of ubiquitinated membrane receptors. This pathway is responsible for cargo incorporation into ILVs, linking ALIX directly to cargo sorting and exosome biogenesis (Baietti et al., 2012). Therefore, in addition to altering EGFR activity, ALIX KD may also affect the quality and composition of exosomes, with downstream consequences for tumor biology. Although procedures do not yet exist for the absolute purification of exosomes, sequential ultracentrifugation provides an established technique for the enrichment of extracellular vesicle (EV) subpopulations highly enriched with exosomes. Nanoparticle tracking analysis (NTA) revealed that ultracentrifugation-enriched particles from HCC1954 culture supernatants had a mean modal diameter of 86 nm, which lies within the range of 40–120 nm associated with exosomes (Figure 3A). Examination of these particles by transmission electron microscopy (TEM) revealed cup-shaped morphologies characteristic of exosomes, while immunogold labeling confirmed that they were positive for the exosome marker CD63 (Figure 3B). Western blotting confirmed the presence of the exosomal marker proteins TSG101, CD9, and ALIX (Figure 3C). Immunoblotting analysis revealed the enrichment and loss of positive and negative exosomal markers, respectively, in these ultracentrifugations. A visual analysis of extracellular vesicle preparations from HCC1954 cells stably expressing GFP-CD63 revealed a uniform characteristic of exosomes, while immunogold labeling confirmed that they were positive for the exosome marker CD63 (Figure 3B).

Western blotting confirmed the presence of the exosomal marker proteins TSG101, CD9, and ALIX (Figure 3C). Immunoblotting analysis revealed the enrichment and loss of positive and negative exosomal markers, respectively, in these ultracentrifugations. A visual analysis of extracellular vesicle preparations from HCC1954 cells stably expressing GFP-CD63 revealed a uniform characteristic of exosomes, while immunogold labeling confirmed that they were positive for the exosome marker CD63 (Figure 3B).

To test whether ALIX depletion alters the exosomal proteome of HCC1954 cells, exosomes from the culture supernatants of control and ALIX KD cells were examined by quantitative mass spectrometry. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified a total of 3,700 proteins in the exosomes of parental HCC1954 cells. These included the core exosomal marker proteins CD63, CD9, and CD81 and proteins known to be associated with exosome biogenesis and endosomal trafficking, such as ALIX, syntenin, syndecan, and Rab5 (Figure S3).

Analysis of the exosomal proteome of ALIX KD cells revealed that 12 proteins were significantly downregulated and four were significantly upregulated, when compared with controls (Figure 3D). As expected, ALIX and syntenin (a cytoplasmic adaptor protein known to interact with ALIX as part of the exosome biogenesis machinery; Baietti et al., 2012) levels were significantly diminished in exosomes derived from ALIX KD cells.

**PD-L1 Is Mis-secreted in the Absence of ALIX**

We were intrigued to find that PD-L1, a protein of high clinical relevance because of its role in mediating tumor-associated immunosuppression, was significantly depleted from the exosomes of ALIX-suppressed cells. Basal PD-L1 expression in HCC1954 cells is elevated following cell stimulation with EGF or interferon (IFNγ), the archetypal signaling factor associated with PD-L1 expression (Figures S4A and S4B). Exosomal PD-L1 incorporation correlates with cellular expression levels (Figure 4A), and we discovered that, while IFNγ treatment resulted in the robust induction and sustained expression of PD-L1 in both NTC and ALIX KD cells (Figure S4C), PD-L1 incorporation into exosomes was significantly reduced in ALIX KD cells (Figure 4B). Flow cytometry analysis of cell-surface PD-L1 expression in unstimulated and IFNγ-stimulated cells revealed that surface levels were elevated in ALIX KD cells (Figure 5A). These data suggest that exosomal release of PD-L1 occurs at the expense of surface PD-L1 levels and that ALIX controls the balance of receptor distribution between these membranes.

Because basal levels of PD-L1 are almost undetectable in SKBR3 cells, and are unchanged following EGF or IFNγ treatment (Figure S5A), we used mouse KPB6 tumor cells, which show a robust PD-L1 response to IFNγ (Figure S5B), as an alternative model to confirm the PD-L1 surface expression phenotype. Elevated surface PD-L1 levels were confirmed in ALIX-depleted and IFNγ-stimulated KPB6 cells (Figure S5C).

**ALIX Regulates PD-L1 Sorting onto ILVs**

To gain insight into the mechanism underlying the reduced exosomal packaging and enhanced cell-surface expression of PD-L1 in ALIX KD cells, we examined the subcellular localization of PD-L1. Immunocytochemistry revealed that, in addition to its cell-surface localization, PD-L1 also localized to both the limiting membrane and ILVs of CD63-positive MVBs in IFNγ-treated HCC1954 cells (Figure 5B). This was in agreement with our detection of PD-L1 in the exosomes of IFNγ-treated cells, because ILVs are the intracellular precursors of these extracellular vesicles. In ALIX KD cells, a greater proportion of PD-L1 was found at the limiting membrane of MVBs, rather than within the endosomal lumen (Figure 5B). Because MVBs are small subcellular structures, the presence of discrete intraluminal cargo is difficult to discern by epifluorescence microscopy. We used Rab5 Q71L expression to promote endosomal enlargement, facilitating the distinction between limiting membrane and endosomal lumen, which confirmed the limiting membrane
accumulation and luminal exclusion of PD-L1 in ALIX KD cells (Figure S6A). Interestingly, TEM analysis of MVBs from NTC and ALIX KD cells revealed that budding profiles (luminal invaginations of the limiting membrane of MVBs that are the precursors to ILVs) were more frequently observed in ALIX KD cells, when compared with controls (Figure S6B). When taken together with the immunofluorescence data, these findings suggest that there may be a defect in intra-endosomal budding associated with ALIX depletion. These data suggest that ALIX is required for incorporation of PD-L1 from the limiting membrane into ILVs, which would account for the diminished levels of exosomal PD-L1 and enhanced surface PD-L1 in ALIX-depleted cells.

**ALIX Regulates the Immunosuppressive Properties of BLBC Cells by Regulating Surface PD-L1 Expression**

The observation that loss of ALIX expression is associated with reduced exosomal packaging of PD-L1 and elevated cell-surface expression raises the intriguing possibility that cells with reduced ALIX expression exhibit enhanced immunosuppressive properties. To test this hypothesis, NTC and ALIX KD cells were either untreated or stimulated with IFNγ for 24 hr and co-cultured with activated primary human peripheral blood CD3+ T lymphocytes to observe the effects of co-culture on lymphocyte proliferation. Flow cytometry analysis of T cells revealed an impairment in the proliferation of T cells co-cultured with ALIX-depleted tumor cells (Figure 5C). These findings demonstrate that ALIX depletion confers enhanced immunosuppressive properties on cancer cells.

Given that PD-L1 expression increases following EGFR or IFNγ receptor activation, and given that ALIX both regulates EGFR activity and modulates the exosomal and cell-surface distribution of PD-L1, we sought to determine whether EGFR signaling integrated with the IFNγ:PD-L1 signaling axis by examining whether the expression and cellular distribution of PD-L1 induced by IFNγ treatment in NTC and ALIX KD cells...
was dependent upon EGFR. Treatment of ALIX KD cells with the EGFR inhibitor PD168393 prior to IFNγ stimulation both diminished the surface accumulation of PD-L1 (Figure 5A) and reduced the immunosuppressive effect of these cells in subsequent co-culture assays (Figure 5C). These data indicate that EGFR signaling contributes to the IFNγ- and PD-L1-dependent immunosuppressive response and suggest that ALIX integrates the signaling of two important regulators of tumor-mediated immunosuppression, modulating PD-L1 surface expression and the EGFR signaling required for the associated immunosuppressive phenotype.

ALIX and PD-L1 Expression Levels Are Inversely Associated in Human Breast Cancer

Our in vitro data suggest that modulation of ALIX expression provides a mechanism for regulating surface PD-L1 expression. Furthermore, we show that differences in ALIX expression translate into differences in immunomodulatory potency. To examine the relevance of this ALIX:PD-L1 signaling axis in human disease, we performed a tissue microarray analysis of PD-L1 protein expression on 189 tumor samples across different human breast cancer subtypes and combined this with ALIX gene expression analysis using mRNA isolated from matched tissue samples. Our analysis revealed a statistically significant inverse correlation between ALIX mRNA and PD-L1 protein expression in tumor cells (Figures 6A and 6B).
delineate patient subsets for more effective therapies is of significant clinical interest (Carey et al., 2012; Masuda et al., 2012). EGFR and immune checkpoint combination strategies are currently being tested in clinical trials (Ahn et al., 2016), and while PD-L1/PD1 pathway blockade is a promising therapeutic approach in oncology, our understanding of PD-L1 regulation remains incomplete. Future success of combination therapies will depend on better understanding of growth factor:PD-L1 signal crosstalk.

We have shown that ALIX is a negative regulator of EGFR activity, that its depletion significantly augments IFNγ-induced PD-L1 surface expression in human breast cancer cells, and that this upregulation is EGFR activity dependent. We have, therefore, extended the receptor tyrosine kinase (RTK) and immune checkpoint molecular interdependence phenomenon, previously only observed in EGFR mutated lung cancers (Akbay et al., 2013), to BLBC, where PD-L1 expression is frequently observed and where elevated EGFR expression is associated with poor survival.

PD-L1 has been identified in exosomes isolated from urine or plasma (Moon et al., 2011; Sabapatha et al., 2006) but has not previously been detected in the exosomes from cancer cells. Using exosomal proteome profiling, we found that HCC1954 cells package PD-L1 into exosomes and that ALIX depletion impairs this exosomal incorporation. Correlating with impaired ILV and exosomal incorporation of PD-L1, ALIX-depleted cells exhibit enhanced surface levels of PD-L1, conferring an enhanced immunosuppressive phenotype on these cells. The change in partitioning of PD-L1 between the exosomal and cell-surface compartments was associated with an altered pattern of PD-L1 localization at the endosome; namely, a loss of luminal PD-L1 and an accumulation of this protein at the

Figure 5. ALIX Regulates the Immunosuppressive Properties of HCC1954 Cells via a Redistribution of PD-L1
(A) Flow cytometry data and statistical analysis of surface PD-L1 expression in NTC and ALIX KD HCC1954 cells. Bars represent mean fluorescence intensities ± SEM (*p < 0.01, ANOVA).
(B) Top: HCC1954 cells were transfected with indicated siRNAs, treated with IFNγ, fixed, stained using antibodies against endogenous CD63 and PD-L1, and counterstained with DAPI. The percentage of cells displaying endosomal PD-L1 was calculated (bottom left graph, mean ± SD), and the percentages of CD63-positive PD-L1 decorated structures were scored: control, 63 ± 4.2%; ALIX #1, 64 ± 4.7%, n.s. (not significant); ALIX #2, 59 ± 2.7%, n.s. 100 cells per experiment, n = 4. Intraendosomal PD-L1 localization (right graph), was also scored: 3,977 endosomes from 10 fields of view per experiment were scored over 4 independent experiments (mean ± SD, **p < 0.01, two-tailed Student’s t test). Lysates were examined by western blotting. Arrowheads highlight luminal and limiting membrane accumulation of PD-L1 in MVBs of control and ALIX KD cells, respectively. Scale bars, 10 μm.
(C) Cell-tracker dye intensity histograms of CD8+ T cell proliferation from labeled T cell-tumor cell co-culture assays. Cell proliferation indices are shown for each treatment group with their associated SEM (*p < 0.05 versus control group; n: 5 independent experiments for each treatment group). Bar chart summarizes the flow cytometry data of surface PD-1 expression in naive and CD2-, CD3-, and CD28-stimulated CD4+ and CD8+ T cell subpopulations (**p < 0.001, Student’s t test; data are from n = 5 independent experiments).
See also Figures S5 and S6.
limiting membrane. We suggest that defective ILV incorporation of PD-L1 results in impaired exosomal packaging, and upon MVB-PM (plasma membrane) fusion, this results in an elevation of cell-surface PD-L1 that confers an enhanced immunosuppressive phenotype. It should be noted that, given its role in viral budding, ALIX may also contribute to the formation of plasma membrane microvesicles, which could contribute to the PD-L1 cell-surface phenotype. However, our immunocytochemistry data indicate that defective trafficking (limiting membrane to ILV) of PD-L1 within MVBs is likely to be a major contributor to this phenotype.
Ex vivo quantitative immunofluorescence analysis of 67NR mouse tumor tissue sections revealed an intratumoral association between areas of low ALIX:PD-L1 expression ratio and a reduced CD3+ lymphocytic infiltration. While this association was significant, it should be noted that it was not observed uniformly, and it is likely that analysis was confounded by the presence of non-tumor cell types expressing ALIX and PD-L1. Spectral deconvolution of more cell-type-specific fluorescent markers will be required to delineate further this phenomenon of relative T cell exclusion from low-ALIX, high-PD-L1 tumor cells.

Figure 7. ALIX Deficiency in an In Vivo Model of Breast Cancer Induces an Immunosuppressive Tumor Microenvironment
(A) Breast tumors were induced by bilateral subcutaneous injection with control (black circle) or ALIX-KD (black triangle) 67NR cells and were monitored for up to 14 days. Western blot demonstrates stable KD of ALIX in 67NR cell lines.

(B and C) Tumor immune cell infiltrate was analyzed for the presence of regulatory T cells (B; Treg, CD4+CD25+Foxp3+) and cytotoxic T cells (C; Granzyme B expression). Plots shown are derived from gates for live CD45+CD3+ cells. The results in the three panels are representative of 8 NTC and 16 short hairpin (sh)ALIX tumors growing in 4 and 9 mice, respectively. Data for the two stable ALIX shRNA 67NR cell lines were pooled for the analysis.

The generation of stable ALIX-suppressed 67NR cells enabled us to address directly the pathophysiological consequences of ALIX depletion on tumor growth and immunosuppression. 67NR cells can be used with immunocompetent BALB/c mice as a syngeneic model of breast cancer and provide an ideal tool to study tumor–immune interplay in this disease. Our in vivo studies revealed that ALIX-KD tumors were both larger than control tumors and associated with an enhanced immunosuppressive phenotype that included elevated numbers of infiltrating T-regulatory cells and decreased numbers of granzyme-B-expressing, tumor-infiltrating CD4+ and CD8+ T cells.

Taken together, our data strengthen the link between the tumor microenvironment and suppression of the immune system in human breast cancers by shedding light on the signaling interplay between EGFR, ALIX, and PD-L1. These data will open additional avenues for therapeutic strategies and accelerate biomarker discovery programs to optimize future combinations between EGFR and immune check-point targeting.

EXPERIMENTAL PROCEDURES

Antibodies
Details of antibodies used in this study are provided in Table S4.

Cell Culture
Human HCC1954 and SKBR3 breast cancer cells were cultured in RPMI 1640 and DMEM, respectively. Mouse 67NR breast and KPB6 lung cancer cells were cultured in DMEM and IMEM, respectively. Culture media was supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cell lines stably expressing NTC and ALIX shRNAs were generated by lentiviral transduction using the pGIPZ system (GE Healthcare UK, Buckinghamshire, UK). Stable cultures of virally transduced cells were established by puromycin selection.

### High-Content siRNA Screen

The custom-designed Silencer Select Human siRNA Library, comprising siRNAs for 533 human gene targets (three siRNAs per target), was from Applied Biosystems. siRNA dilutions, transfection complex preparation, and cell seeding were performed using a Janus automated workstation (PerkinElmer). Each siRNA was evaluated in triplicate, and each experiment was performed three times. Cells were seeded in the presence of transfection complexes (0.5 pmol siRNA; RNAiMAX reagent, Invitrogen, Carlsbad, CA, USA) and, after 24 hr, were transfected with the Picchu-X biosensor using FuGENE HD reagent (Promega, Fitchburg, WI, USA). After an additional 24 hr, cells were treated with or without 100 ng/mL EGF for 30 min before fixation and FLIM analysis. Control siRNA vectors were cells included alongside target siRNA cells to enable pairwise comparisons. siRNAs against human PDCD6IP were purchased from Horizon Discovery (Cambridge, UK). PDCD6IP siRNAs #1 and #2 refer to siGENOME IDs D-004233-01-0002 and D-004233-06-0002, respectively. siGENOME Non-Targeting siRNA ID D-001210-02-05 was used as the control. Lentiviral shRNA vectors for the stable KD of human and mouse PDCD6IP were purchased from GE Healthcare UK. For stable KD of human PDCD6IP, Clone ID V2LHS_357889 was used. For stable KD of murine Pdcd6ip, Clone IDs V2LMM_177842 and V3LMM_450035 were used.

### FLIM Analysis

FLIM was used to measure FRET between the donor and acceptor fluorophores of the biosensor in cells treated with or without EGF. Because high biosensor expression increases the probability of intermolecular FRET between the donor and acceptor fluorophores of neighboring proteins through molecular crowding, such effects were considered in the analysis of intramolecular FRET (desired component). Intermolecular FRET was determined by analyzing the lifetime of the donor fluorophore at increasing concentrations of biosensor expression (determined by fluorescence intensity). Pearson correlation was used to examine the correlation between lifetime and intensity. Regression analyses were further used to quantify associations between EGF treatment, intensity, and lifetime. Tests for an interaction incorporating the product term of EGF treatment and intensity were performed to assess whether effects of EGF on lifetime differed by intensity. A lack of significant interaction indicated that the association between lifetime and EGF treatment was not affected by intensity (Figure 1E). Analyses of covariance (ANCOVA) were performed to further discern the effect of EGF treatment, with intensity and EGF treatment as predictor variables and biosensor lifetime as the dependent variable. Lifetime and intensity data were normally distributed. All statistical analyses were performed with R v3.1.2 (R Project for Statistical Computing, Vienna, Austria). Two-tailed p values < 0.05 were considered statistically significant. In all cases, data are presented as mean ± SEM.

### Construction of the Picchu-X Biosensor

The Picchu-X sensor for reporting EGFR kinase activity was a kind gift from M. Matsuda, Osaka University, Osaka, Japan (Kurokawa et al., 2001). The C-terminal membrane-targeting CAAX motif was not affected by intensity (Figure 1E). Analyses of covariance (ANCOVA) indicated that the association between lifetime and EGF treatment whether effects of EGF on lifetime differed by intensity. A lack of significant interaction interaction indicated that the association between lifetime and EGF treatment was not affected by intensity (Figure 1E). Analyses of covariance (ANCOVA) were performed to further discern the effect of EGF treatment, with intensity and EGF treatment as predictor variables and biosensor lifetime as the dependent variable. Lifetime and intensity data were normally distributed. All primary antibodies used are listed in Table S4. Densitometry analysis of protein band (western blots) and spot (dot-blotting) intensities were performed using ImageJ software. Data reported in bar graphs were obtained from ≥3 independent experiments.

### Immunoblotting Assays

Western blotting was performed according to standard protocols. Dot-blotting was used to examine protein content of EVs due to its improved sensitivity compared with western blotting and involving the immunodetection of proteins spotted onto nitrocellulose membranes (1 μg total protein in 5 μL). All primary antibodies used are listed in Table S4. Densitometry analysis of protein band (western blots) and spot (dot-blotting) intensities were performed using ImageJ software. Data reported in bar graphs were obtained from ≥3 independent experiments.

### Confocal Imaging

HCC1954 cells were transfected with ALIX siRNA (40 nM) using RNAiMAX. After 48 hr, cells were treated with IFNγ (20 ng/mL) for 24 hr. Cells were fixed with PFA and stained for CD63 and PD-L1. Nuclei were counterstained with DAPI. Cells were imaged on a spinning disk confocal microscope (Nikon Eclipse, teamed with the CSU-X1 Andor Spinning Disk with Neo sCMOS camera), acquiring sub-saturated images as z stacks with 0.3-μm Z-spacing. At least 10 fields of view per treatment were captured, and luminal versus limiting membrane staining of endosomal PD-L1 was scored by manually scrolling through Z.

### Tumor Cell-T Cell Co-culture Assays

Peripheral blood mononuclear cells (PBMCs) from healthy donor blood were collected by sucrose gradient centrifugation using Ficoll (GE Healthcare). CD3+CD25- cells were subsequently isolated using magnetic beads (Miltenyi Biotec), labeled with eFluor 450 cell-tracker dye, and then activated with CD3, CD2, and CD28 beads at the time of co-culture with tumor cells. At 96 hr post-co-culture, cells were recovered and stained with CD3, CD4, CD8, and PD-1 antibodies and then subjected to flow cytometry. Data were analyzed using FlowJo software (FlowJo, Ashland, OR, USA). The significance of statistical differences between treatment groups was determined using ANOVA (p < 0.05 was reported as significant).

### In Vivo Breast Cancer Model

Experiments were performed in accordance with the UK Home Office Animals Scientific Procedures Act, 1986, and the United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines. Tumors were established by subcutaneous injection of 1 × 10^6 cells of the syngeneic mouse breast cancer cell line 67NR (Aslakson and Miller, 1992) into the mammary fat pad of 6- to 8-week-old BALB/c female mice (Charles River UK). Tumor growth was monitored with calipers and recorded every other day for 2 weeks; then, mice were culled and primary tumors were dissected. Tumors were minced and incubated for 1 hr at 37°C in digestion media (RPMI containing 1 mg/mL type 2 collagenase and 0.1 mg/mL bovine pancreas DNase I) and passed through a 40-μm cell strainer to form single-cell suspensions for flow cytometry.
Flow Cytometry
Cell suspensions were stained with Zombie Aqua dye, followed by membrane staining with anti-CD45-APC700, CD3-PECy7, CD4-BV785, CD8-PerCPCy5.5, and CD25-PE; fixation and permeabilization; and intracellular staining with anti-Foxp3-eFluor 450 or Granzyme B-APC. Stained cell suspensions were analyzed by flow cytometry. Data were acquired in a Fortessa II flow cytometer (BD Biosciences) and analyzed with FlowJo software (FlowJo).

Patient Samples and Immunohistochemistry
Tissues and data were collected by the KHP Cancer Biobank with approval from the East of England – Cambridge East Research Ethics Committee, reference number 12/EE/0493. Tissue microarrays (TMAs) of 218 primary breast cancers from the METABRIC study (Curtis et al., 2012) were used in this analysis. After antigen retrieval using the Ventana BenchMark system (Ventana Medical Systems), tissues were stained with anti-PD-L1 antibody. A total of 189 TMA cores were imaged using an “open” high-content microscope (Barber et al., 2013), and image data were subsequently processed to determine protein expression. To find the percentage of PD-L1-positive cancer cells, we adopted a previously reported algorithm (Camp et al., 2002; Moeder et al., 2009; Wimberly et al., 2015).

For the evaluation of ALIX mRNA expression, Illumina HT-12 microarray expression data were obtained from all METABRIC samples and filtered to remove arrays with outlying low intensity (mean log2 expression < 5.6). Array data were then quantile-normalized, filtered for probe detection (required p < 0.01 for >1% of King’s METABRIC samples), and COMBAT-corrected for batch effects. Normalization was performed using the “beadarray” package for R/Bioconductor (Dunning et al., 2007). ALIX (PDCD6IP) mRNA expression was inspected using Probe identifier ILMN_1693259. Gene expression data from the METABRIC study have been reported previously (Curtis et al., 2012). The correlation between PD-L1 positivity and ALIX mRNA tissue expression was tested using GraphPad statistical analysis software.

Tissue samples and data from patients were obtained from The King’s Health Partners (KHP) Cancer Biobank at Guy’s Hospital (London, UK; REC no.: 07/40874/131).

SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and four tables and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.06.066.

ACKNOWLEDGMENTS
The authors thank Pascale Zimmermann for discussion and advice on ALIX signaling and exosome biology. We also thank Susanne Heck, Anna Rose, and Rianne Wester in the Biomedical Research Center, Flow Cytometry Research Platform, Guy’s Hospital, London, and the Nikon Imaging Centre at King’s College London. This work was supported by Cancer Research UK (grants C1519/A6906 and C2525/A15933); by the King’s College London-UCL Comprehensive Cancer Imaging Centre (CRUK and EPSRC, grants C1519/A10331 and C1519/A16463), in association with the MRC and DoH (grants C1519/A6906 and C5255/A15935); by the King’s College London-University of Kent Cancer Research Platform, Guy’s Hospital, London, and the Nikon Imaging Centre; and by KCL Breast Cancer Now Unit funding (for F.F.-B.; grant KCL-Q2-Y5). The purchase of the siRNA library was possible thanks to a generous gift from Ms. Madame Bollard.

AUTHOR CONTRIBUTIONS
T.N. conceived, supervised, and secured funding for the project. J.M., H.M., F.F.-B., G.W., and J.G.C. conceived and conducted experiments. A.C., R.C., T.B., and A.A. conducted experiments. K.L., P.R.B., W.W., and A.V.K. conducted data analysis. J.M.V., M.K., N.W., A.V.K., M.T., D.F., and B.V. provided technical expertise. C.G. and S.M.D. provided resources and expertise. S.A.O., F.F., C.E.F., and W.K. provided expertise and intellectual feedback. T.N., J.G.C., and J.M. wrote the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: October 17, 2017
Revised: April 23, 2018
Accepted: June 15, 2018
Published: July 17, 2018

REFERENCES
Ahn, M.J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K., Kim, S.W., Yang, L., Walding, A., and Oxnard, G.R. (2016). 1360: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase ib trial. J. Thorac. Oncol. 11 (4, Suppl), S115.
Akbay, E.A., Yokoyama, S., Carretero, J., Attalib, A., Tchaicha, J.H., Christensen, C.L., Mikse, O.R., Chemnack, A.D., Beauchamp, E.M., Pugh, T.J., et al. (2013). Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355–1363.
Aslaksen, C.J., and Miller, F.R. (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405.
Azuma, K., Ota, K., Kawahara, H., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014). Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small-cell lung cancer. Ann. Oncol. 25, 1935–1940.
Baietti, M.F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geerselaers, A., Ivars, Y., Depoortere, F., Coomans, C., Vermeiren, E., et al. (2012). Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14, 677–685.
Barber, P.R., Tullis, I.D., Pierce, G.P., Newman, R.G., Prentice, J., Rowley, M.I., Matthews, D.R., Amrein-Beg, S.M., and Vojnovic, B. (2013). The Gray Institute ‘open’ high-content, fluorescence lifetime microscopes. J. Microsc. 251, 154–167.
Bertucci, F., Finetti, P., Colpaert, C., Mamessier, E., Parizel, M., Dirix, L., Viens, P., Birnbaum, D., and van Laere, S. (2015). PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget 6, 13506–13519.
Bissig, C., and Gruenberg, J. (2014). ALIX and the multivesicular endosome: ALIX in wonderland. Trends Cell Biol. 24, 19–25.
Buness, M.L., Grushko, T.A., and Olopade, O.I. (2010). Epidermal growth factor receptor factor inhibitor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 16, 23–32.
Camp, R.L., Chung, G.G., and Rimm, D.L. (2002). Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8, 1323–1327.
Carey, L.A., Rugo, H.S., Marcom, P.K., Mayer, E.L., Esteva, F.J., Ma, C.X., Liu, M.C., Storniolo, A.M., Rimawi, M.F., Forero-Torres, A., et al. (2012). TBRC001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30, 2615–2623.
Carlton, J. (2010). The ESCRT machinery: a cellular apparatus for sorting and scission. Biochem. Soc. Trans. 38, 1397–1412.
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015). Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J. Thorac. Oncol. 10, 910–923.
Chong, C.R., and Jänne, P.A. (2013). The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1399–1400.
Ciardiello, F., and Tortora, G. (2008). EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160–1174.
Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiva, S., Yuan, Y., et al.; METABRIC Group (2012). The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346–352.

Dragovic, R.A., Gardiner, C., Brooks, A.S., Tannetta, D.S., Ferguson, D.J., Hole, P., Carr, B., Redman, C.W., Harris, A.L., Dobson, P.J., et al. (2011). Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine (Lond.) 7, 780–788.

Dunning, M.J., Smith, M.L., Ritchie, M.E., and Tavare, S. (2007). beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183–2184.

Ghossoub, R., Lembo, F., Rubio, A., Gaillard, C.B., Bouchet, J., Vitale, N., Slavik, J., Machala, M., and Zimmermann, P. (2014). Syntenin-ALIX exosome biogenesis and budding into multivesicular bodies are controlled by ARF6 and PLD2. Nat. Commun. 5, 2477.

Hashimoto, Y., Katayama, H., Kiyokawa, E., Ota, S., Kurata, T., Gotoh, N., Otsuka, N., Shibata, M., and Matsuda, M. (1998). Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor. J. Biol. Chem. 273, 17186–17191.

Hudis, C.A., and Gianni, L. (2011). Triple-negative breast cancer: an unmet medical need. Oncologist 16 (Suppl 1), 1–11.

Irshad, S., Ellis, P., and Tutt, A. (2011). Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr. Opin. Oncol. 23, 566–577.

Komatsu, N., Aoki, K., Yamada, M., Yukinaga, H., Fujita, Y., Kamioka, Y., and Matsuda, M. (2011). Development of an optimized backbone of FRET biosensors for kinases and GTPases. Mol. Biol. Cell 22, 4647–4656.

Kurokawa, K., Mochizuki, N., Ohba, Y., Mizuno, H., Miyawaki, A., and Matsuda, M. (2001). A pair of fluorescent resonance energy transfer-based probes for tyrosine phosphorylation of the CrkII adaptor protein in vivo. J. Biol. Chem. 276, 31305–31310.

Masuda, H., Zhang, D., Bartholomeusz, C., Dohara, H., Horta, D., and Ueno, N.T. (2012). Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res. Treat. 136, 331–345.

Moeder, C.B., Giltinan, J.M., Moulin, S.P., and Rimme, D.L. (2009). Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol. Biol. 520, 163–175.

Moon, P.G., Lee, J.E., You, S., Kim, T.K., Cho, J.H., Kim, I.S., Kwon, T.H., Kim, C.D., Park, S.H., Hwang, D., et al. (2011). Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 11, 2459–2475.

Murillo, M.M., Zelenay, S., Nye, E., Castellano, E., Lassailly, F., Stamp, G., and Downward, J. (2014). RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J. Clin. Invest. 124, 3601–3611.

Nielsen, T.O., Hsu, F.D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Lvisy, C., Cowan, D., Dressler, L., et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367–5374.

Nuciforo, P., Radosevic-Robin, N., Ng, T., and Scaltriti, M. (2015). Quantification of HER family receptors in breast cancer. Breast Cancer Res. 17, 53.

Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264.

Sabapatha, A., Gercel-Taylor, C., and Taylor, D.D. (2006). Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences. Am. J. Reprod. Immunol. 56, 354–355.

Sabatier, R., Finetti, P., Mamesier, E., Adeleade, J., Chaffanet, M., Ali, H.R., Viens, P., Caldas, C., Birmbaum, D., and Bertucci, F. (2015). Prognostic and predictive value of PD-L1 expression in breast cancer. Oncotarget 6, 5449–5464.

Soliman, H., Khalil, F., and Antonia, S. (2014). PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE 9, e88557.

Turriziani, B., Garcia-Munoz, A., Pilkington, R., Rasolo, C., Kolch, W., and von Kriegsheim, A. (2014). On-beads digestion in conjunction with data-dependent mass spectrometry: a shortcut to quantitative and dynamic interaction proteomics. Biology (Basel) 3, 320–332.

Vega, F.M., Fruhwirth, G., Ng, T., and Ridley, A.J. (2011). RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J. Cell Biol. 193, 655–665.

Wimberly, H., Brown, J.R., Schalper, K., Haack, H., Silver, M.R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D.R., and Rimme, D.L. (2015). PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol. Res. 3, 326–332.